AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?

Source: Yahoo Entertainment· Noor Ul Ain Rehman· August 23, 2026
AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?

AstraZeneca PLC (NYSE:AZN) is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd, adding another targeted the...

This story was reported by Yahoo Entertainment. Read the full original article:
Read on Yahoo Entertainment

More in Business & Funding

View all